

Table 3.10	RSD% for each of the calibration points of amlodipine	45
Table 3.11	RSD% for each of the calibration points of glimepiride	46
Table 3.12	RSD% for each of the calibration points of atorvastatin	46
Table 3.13	RSD% for each of the calibration points of amlodipine in plasma	48
Table 3.14	RSD% for each of the calibration points of glimepiride in plasma	48
Table 3.15	RSD% for each of the calibration points of atorvastatin in plasma	49
Table 3.16	Accuracy for the determination of amlodipine	49
Table 3.17	Accuracy for the determination of glimepiride	49
Table 3.18	Accuracy for the determination of atorvastatin	50
Table 3.19	Stability for amlodipine, glimepiride and atorvastatin in diluent solution	52
Table 3.20	Stability for amlodipine, glimepiride and atorvastatin in plasma	52
Table 3.21	Effect of changing the wavelength detection by -3nm on the detection parameters	53
Table 3.22	Effect of changing the wavelength detection by +3nm on the detection parameters	53
Table 3.23	Effect of changing the wavelength detection by -3nm on the detection parameters in plasma	55
Table 3.24	Effect of changing the wavelength detection by +3nm on the detection parameters in plasma	55
Table 3.25	Effect of changing the pH -0.2 on the detection parameters.	56